Compare FSBW & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSBW | NGEN |
|---|---|---|
| Founded | 1936 | 2017 |
| Country | United States | Canada |
| Employees | 537 | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 317.6M |
| IPO Year | 2011 | N/A |
| Metric | FSBW | NGEN |
|---|---|---|
| Price | $39.77 | $3.99 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $46.00 | N/A |
| AVG Volume (30 Days) | 8.5K | ★ 98.1K |
| Earning Date | 04-21-2026 | 04-02-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.29 | N/A |
| Revenue | ★ $4,612,000.00 | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $8.63 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $34.61 | $3.55 |
| 52 Week High | $44.22 | $5.93 |
| Indicator | FSBW | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 45.59 |
| Support Level | $37.62 | $3.69 |
| Resistance Level | $40.79 | $4.10 |
| Average True Range (ATR) | 1.26 | 0.24 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 72.60 | 53.99 |
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.